MRK

Merck & Co., Inc.

N/A • FY2025 Annual Report

NYSE H-1B Visa Sponsor Revenue +1.3% YoY

Revenue

$65.0B

Net Income

$18.3B

EBIT Margin

N/A

Diluted EPS

$7.28

Free Cash Flow

$12.4B

CEO Pay

$20,797,845

Robert M. Davis

56%

of Merck & Co., Inc.'s revenue comes from United States

Companies claim they must hire overseas workers because that's where their business is. The data says otherwise: Merck & Co., Inc. generates 56% of its $36.5B revenue from United States, yet continues to file H-1B petitions that displace American workers.

$20,797,845

Robert M. Davis's total compensation in FY2025

Base salary $1,645,302 • Stock awards $12,102,838. The CEO's pay package is funded by the same company that claims it cannot find qualified American workers for its open positions.

Financial Snapshot — FY2025

Total Revenue

$65.0B

+1.3% year-over-year

Net Income

$18.3B

Operating Margin

N/A

Diluted EPS

$7.28

Free Cash Flow

$12.4B

Dividend / Share

N/A

Stock Buybacks

N/A

Where the Revenue Comes From — FY2025

United States

$36.5B

56%

International

$28.5B

44%

Revenue earned in the United States contradicts the claim that H-1B workers are needed because “that’s where the business is.” Source: SEC EDGAR 10-K, FY2025.

What We Pay the Executives Source: SEC DEF 14A via sec-api.io

CEO Total Compensation

$20,797,845

Robert M. Davis

CEO Base Salary

$1,645,302

CEO Stock Awards

$12,102,838

Avg. Other NEO Total

N/A

Executive	Title	Base Salary	Stock Awards	Total Comp
Robert M. Davis🔍	Chairman, Chief Executive Officer and President	$1,645,302	$12,102,838	$20,797,845
Dean Li, M.D., Ph.D.🔍	Executive Vice President and President, Merck Research Laboratories	$1,460,000	$4,296,864	$8,892,881
Caroline Litchfield🔍	Executive Vice President and Chief Financial Officer	$1,173,214	$3,580,681	$7,514,085
Jennifer Zachary🔍	Executive Vice President and General Counsel	$1,062,217	$2,685,571	$5,860,578
Sanat Chattopadhyay🔍	Executive Vice President and President, Merck Manufacturing Division	$982,170	$2,363,261	$5,408,408

SCT = Summary Compensation Table totals from SEC EDGAR DEF 14A proxy statement.

Board of Directors — Who Enables This

Director	Role	Age	Independent	Since	Tenure	Annual Pay	Committees
Christine E. Seidman, M.D.🔍	Director Nominee	73	Yes	N/A	N/A	N/A
Douglas M. Baker, Jr.🔍	Director Nominee	67	Yes	N/A	N/A	N/A	Audit Committee
Dr. Lavizzo-Mourey🔍	Chair of the Governance Committee	None	Yes	N/A	N/A	N/A	Governance Committee
Dr. Mayo🔍	Director	None	Yes	N/A	N/A	N/A
Dr. Rothman🔍	Director	None	Yes	N/A	N/A	N/A	Quality & Compliance Committee
Inge G. Thulin🔍	Director Nominee	72	Yes	N/A	N/A	N/A
Kathy J. Warden🔍	Director Nominee	54	Yes	N/A	N/A	N/A
Mary Ellen Coe🔍	Director Nominee	59	Yes	N/A	N/A	N/A
Pamela J. Craig🔍	Director Nominee	69	Yes	N/A	N/A	N/A	Compensation and Talent Committee, Information Technology Committee, Audit Committee
Patricia F. Russo🔍	Director Nominee	73	Yes	N/A	N/A	N/A	Governance and Corporate Responsibility Committee
Paul B. Rothman, M.D.🔍	Director Nominee	68	Yes	N/A	N/A	N/A	Research Committee
Risa J. Lavizzo-Mourey, M.D.🔍	Director Nominee	71	Yes	N/A	N/A	N/A
Stephen L. Mayo, Ph.D.🔍	Director Nominee	64	Yes	N/A	N/A	N/A
Surendralal L. Karsanbhai🔍	Director Nominee	56	Yes	N/A	N/A	N/A	Chair of the Federal Reserve Bank of St. Louis, Trustee of Washington University, Audit Committee
Thomas H. Glocer🔍	Lead Director	66	Yes	N/A	N/A	N/A	Governance Committee

Source: SEC EDGAR DEF 14A proxy statement via sec-api.io.

H-1B Visa Dependency Key Metric

Search all Merck & Co., Inc. H-1B Labor Condition Applications filed with the U.S. Dept. of Labor.

🔍 Search H-1B Records for Merck & Co., Inc.

Source: U.S. Dept. of Labor OFLC disclosure data. LCA filing does not guarantee a visa was issued.

Shareholder Value Assessment

WatchRevenue grew only 1.3% year-over-year - at or below inflation.

PositiveNet margin of 28.1% - highly profitable.

WatchCEO received $21M in compensation.

Key Business Risks (from 10-K Item 1A)

Environmental, social and governance matters may impact the Company’s business and reputation — Governmental authorities, non-governmental organizations, customers, investors, external stakehold
Pharmaceutical products can develop unexpected safety or efficacy concerns — Unexpected safety or efficacy concerns can arise with respect to marketed products, whether or not scientifically justified
Developments following regulatory approval or authorization may adversely affect sales of the Company’s products — Even after a product reaches the market, certain developments following regulat
Adverse outcomes in current or future legal matters could negatively affect the Company’s business — Current or future litigation, claims, proceedings and government investigations could preclud
Product liability insurance for products may be limited, cost prohibitive or unavailable — As a result of a number of factors, product liability insurance has become less available while the cost of s

♥

Help Support This Research

This analysis is produced independently — one person, 23 years of data work, living on $1,419/month Social Security. If these reports help you understand how H-1B visas affect American workers, a small donation makes a real difference.

♥ Donate via Square More Reports

Merck & Co., Inc.

of Merck & Co., Inc.'s revenue comes from United States

Robert M. Davis's total compensation in FY2025

Help Support This Research

💬 Comments & Discussion